#NephJC Transcript
Healthcare social media transcript of the #NephJC hashtag.
โ ().
See #NephJC Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Nikhil Shah MBBS DNB(IM, Neph)๐จ๐ฆ @dr_nikhilshah @KidneyCathy All set, best luck. Get your coffee first!! Quick. #nephjc https://t.co/7PWvMT41UR |
 | Nephrology Journal Club @NephJC Itโs 11am in Melbourne and time for #nephjc Letโs get this party started! |
 | Cathy Quinlan @CathyQuinlan.bsky.social @KidneyCathy Itโs 11am in Melbourne and time for #nephjc Letโs get this party started! https://t.co/NdpnXH8a3q |
 | Joel M. Topf, MD FACP @kidney_boy RT if you had a crush on Olivia Newton John. Fav if you are too young to know who the hell that is. #nephjc |
| Nephrology Journal Club @NephJC Need a quick catch up before diving into #nephjc โ read the summary from @toates_19 https://t.co/ebwCREJyP5 |
 | Edgar V. Lerma ๐ต๐ญ @edgarvlermamd Edgar Lerma, Chicago-based Nephrologist #NephJC https://t.co/7Yb9ocrH0S |
| Joel M. Topf, MD FACP @kidney_boy Tom knocked it out of the park MT @NephJC: Need a quick catch up? โ read the summary from @toates_19 https://t.co/s3LZHR2nJA #nephjc |
| Joel M. Topf, MD FACP @kidney_boy hey Edgar, nice to see you. How have you been? #nephjc |
 | Poyan Mehr @poyanmehr Ali Poyan Mehr from Boston #nephjc |
 | Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @gratefull080504 : joining the #nephJC chat from #Detroit tonight Enjoyed reviewing the JASN article ! https://t.co/rvUodmxC3l |
 | Michelle Rheault @rheault_m @kidney_boy I've watched Grease approximately 800 times #nephJC. I wanted to be her. https://t.co/mnDhvPInJf |
| Nephrology Journal Club @NephJC We recommend using https://t.co/rFoH4MEbaU or TChat.io to follow the #nephjc chat. See a how to guide here: http//www.nephjc.com/how-to/ |
 | Anitha Vijayan @VijayanMD Anitha Vijayan @WUNephrology. No COI #NephJC |
| Joel M. Topf, MD FACP @kidney_boy It's like being on the Nebuchadnezzar from the Matrix https://t.co/oSifuU5q9B |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd @kidney_boy Just hangin' #NephJC https://t.co/lKEwY4oA3h |
| Nephrology Journal Club @NephJC Remember to add #NephJC to every tweet you want to be part of the discussion and part of the recorded journal club |
| Michelle Rheault @rheault_m @NephJC Michelle Rheault here. Ped Neph UMN. Lurking tonight. #Nephjc can't compete with ice cream and balloon animals at KidFest https://t.co/ssAcJ2N8zH |
| Nephrology Journal Club @NephJC Welcome to #NephJC please introduce yourself and declare any conflict of interests (COI) even if youโre only planning on lurking |
| Nephrology Journal Club @NephJC Iโm Cathy Quinlan. I will be hosting and tweeting as @KidneyCathy & @KidGenAustralia. Paed neph & clinician researcher in Melbourne. #NephJC |
 | Bea Concepcion @KidneyBea_n Hello! Bea Concepcion #NSMC 2017 @VUMCKidney, No COI #nephjc |
| Cathy Quinlan @CathyQuinlan.bsky.social @KidneyCathy Iโm Cathy Quinlan. Tweeting as @KidneyCathy & @KidGenAustralia. No COI as not important enough (yet) #NephJC |
| Joel M. Topf, MD FACP @kidney_boy Hey Bea and Anitha, thanks for coming #nephjc |
| Nephrology Journal Club @NephJC @KidneyBea_n @VUMCKidney Welcome to #NephJC and thanks for joining us! |
 | Hector Madariaga, MD FASN ๐ฒ๐ฝ @HecmagsMD Hector Madariaga. No COI. From #PatriotsNation. Hi, everyone! #NephJC https://t.co/MKv6wFK0Ae |
| Nephrology Journal Club @NephJC Hi @edgarvlermamd thanks for joining #nephjc |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @gratefull080504 : COI: Protalix Biotherapeutics #nephJC https://t.co/cecIl0dHWh |
| Nephrology Journal Club @NephJC Hi @HecmagsMD thanks for joining #nephjc |
| Nephrology Journal Club @NephJC Hi @gratefull080504, looking forward to your insights! #nephjc |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd Pathogenesis of ANCA Vasculitis #NephJC ๐๐ผ https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw |
 | Arvind Canchi (Conjeevaram)๐ฎ๐ณ @arvindcanchi #NephJC Arvind Canchi Nephrologist from Bangalore. No coi. |
 | Paul Sufka, MD @psufka #nephjc Paul Sufka. Rheumatologist from St Paul, MN. Thanks for inviting the #RheumJC folks! COI: trying to put our 4yo to bed. |
| Nephrology Journal Club @NephJC Welcome to #NephJC even if youโre only planning on lurking, please introduce yourself โ itโs nice to know youโre there! |
| Joel M. Topf, MD FACP @kidney_boy Hey Hector, I was talking to Howard, you up for another round of Fantasy Football? #nephjc |
 | Silvi Shah, MD, MS @silvishah Hi this is Silvi from Cincinnati #NephJC |
| Joel M. Topf, MD FACP @kidney_boy Hi Silvi, thanks for coming #nephjc |
| Hector Madariaga, MD FASN ๐ฒ๐ฝ @HecmagsMD @KidneyCathy Hi Cathy. Please stay away from water! Hope all is well ๐ @kidgenaustralia #nephjc |
| Nephrology Journal Club @NephJC Remember one of the core goals of #nephJC is to build a personal learning network so make sure to hit the follow button. https://t.co/kcyNd6P5n4 |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @NephJC thank you @NephJC #nephJC |
| Hector Madariaga, MD FASN ๐ฒ๐ฝ @HecmagsMD @kidney_boy absolutely! I'm in. I hope to draft Jay Cutler #nephjc |
| Nephrology Journal Club @NephJC Diving straight into the methodology - what did you think of the study design? Lots of potential criticism of parallel groups. #nephjc |
 | Gates Colbert, MD @DoctorGates Dallas based Nephrologist. Frequent ANCA vasculitis treater. #Plasmapheresis #NSMC2017 No COI #nephjc |
 | Pablo Garcia @PabloGarciaMD Pablo Garcia New Brunswick, NJ. #NSMC intern 2017. No CoI. #nephjc |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC ๐๐ผ https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H |
| Nephrology Journal Club @NephJC @kevo00o @NephJC great to have you here - remember to hit the follow button! #nephjc |
 | Sanjeev Nair @Nair_Sanj Sanjeev Nair from Chennai. No CoI. #nephjc |
| Nephrology Journal Club @NephJC Terrific summary (as always) from #nephpearls #nephjc https://t.co/FRGZuStKR5 |
| Cathy Quinlan @CathyQuinlan.bsky.social @KidneyCathy Lots for neph to learn from rheum community especially their use of standardised outcomes @song_initiative #nephjc |
 | Anna Burgner MD MEHP @anna_burgner Hey all! Sorry I'm late! Clinical nephrologist @VUMCKidney with no coi #nephjc |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo |
| Nephrology Journal Club @NephJC @anna_burgner @VUMCKidney Hi Anna - really just getting started! #nephjc |
| Sanjeev Nair @Nair_Sanj RT @edgarvlermamd: Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC ๐๐ผ https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H |
| Michelle Rheault @rheault_m RT @edgarvlermamd: Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC ๐๐ผ https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H |
| Nephrology Journal Club @NephJC As before - really don't need to look anywhere else #nephpearls #nephjc https://t.co/V19OnM8ckc |
| Poyan Mehr @poyanmehr @NephJC i thought the study design seems relatively standard for a phase II trial. #nephjc |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Do all #patients with #vasculitis have progress to #ESRD ? #nephJC |
| Poyan Mehr @poyanmehr @NephJC but the nature of that purpose doesn't come across in the manuscript #nephjc |
| Nephrology Journal Club @NephJC Does anyone want to weigh in on the parallel group comparison methodology? #nephjc |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC ๐๐ผ https://t.co/ERXMI3qFB8 https://t.co/qmnoDphueD |
 | J. Brian Byrd Lab @thebyrdlab Hi all: Brian Byrd, Ann Arbor, lurking this time & waiting for things to circle back to ... blood pressure! ๐ #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 asking again #nephJC https://t.co/33ijoK5WN4 |
| Poyan Mehr @poyanmehr @gratefull080504 @NephJC no, definitely no #nephjc |
 | Abraham E. Gracia R. @Abraham_RMI RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC ๐๐ผ https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw |
| Nephrology Journal Club @NephJC @gratefull080504 No they don't all progress. #nephjc |
| Poyan Mehr @poyanmehr using the first time tchat,io and desktop, so trying to get handle on this #nephjc |
| Abraham E. Gracia R. @Abraham_RMI RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC ๐๐ผ https://t.co/ERXMI3qFB8 https://t.co/qmnoDphueD |
 | Patrick D Walker @Trumidor Pat Walker Arkana Labs lurking #nephjc |
 | Wings Implied @Wingsimplied RT @kidney_boy: RT if you had a crush on Olivia Newton John. Fav if you are too young to know who the hell that is. #nephjc |
| Nephrology Journal Club @NephJC @S_brimble @silvishah welcome! #nephjc |
| Paul Sufka, MD @psufka RT @edgarvlermamd: Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC ๐๐ผ https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 What percent do? The article stated 18-35% do in 5 years #nephJC https://t.co/PkhBAhcfk0 |
| Gates Colbert, MD @DoctorGates @gratefull080504 Definitely not. Many #Vasculitis pts show great recovery, but still likely CKD from the AKI #NephJC |
| Paul Sufka, MD @psufka RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo |
| Cathy Quinlan @CathyQuinlan.bsky.social @KidneyCathy Which implies that better AKI treatment is key https://t.co/hMSshj25Vm |
 | Gerardo Alfaro @gerardoalfaromd Prรกctico esquema para clasificar las vasculitis #enarm2017 #ENARM https://t.co/GKKaTn4E64 |
| Paul Sufka, MD @psufka RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC ๐๐ผ https://t.co/ERXMI3qFB8 https://t.co/qmnoDphueD |
| Poyan Mehr @poyanmehr RT @NephJC: Does anyone want to weigh in on the parallel group comparison methodology? #nephjc |
| Joel M. Topf, MD FACP @kidney_boy @gratefull080504 Nope, this is a disease we are fairly good at but we lose some. #NephJC |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd Birmingham Vasculitis Activity Score (BVAS) #Nephpearls #NephJC https://t.co/bYPpe3xyt2 |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Is the #ckd then stage 3, or 4? #nephJC https://t.co/hGO2JcR0Ja |
 | Manish Rathi @manirath #NephJC Manish Rathi from Chandigarh, India. No COI. https://t.co/RAONMmWUQe |
| Nephrology Journal Club @NephJC Can a rheumatologist comment on the suitability of the Birmingham score for acute change? #nephJC #RheumJC |
| Joel M. Topf, MD FACP @kidney_boy I thought the study design was appropriately conservative for a novel agent treating a manageable disease #nephjc |
| Nephrology Journal Club @NephJC A huge shout out to our #rheumjc colleagues! Welcome to #nephjc |
| Joel M. Topf, MD FACP @kidney_boy Yes, I had more problems with the low bar they established for an endpoint. #nephjc |
 | Roger Rodby @NephRodby Roger Rodby, too many COIs to count #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Didn't Celeste Lee Castillo have #vasculitis ? #nephJC https://t.co/ulxS3CJroi |
| Nephrology Journal Club @NephJC The concern with complexity is always what is obscured. #nephjc https://t.co/W1eZnVkySs |
 | Raul Reyna @raul_reyna RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo |
| Poyan Mehr @poyanmehr @kidney_boy and most importantly. it was phase II - not meant to look for efficacy but safety #nephjc |
| Roger Rodby @NephRodby I need a #nephpearls for parallel group issue #NephJC |
| Joel M. Topf, MD FACP @kidney_boy RT @poyanmehr: @kidney_boy and most importantly. it was phase II - not meant to look for efficacy but safety #nephjc |
| Gates Colbert, MD @DoctorGates @gratefull080504 It all depends on the eGFR where the patient stabilizes to stage the CKD. Unless you agree with the recent CJASN Aug issue #NephJC |
| Nephrology Journal Club @NephJC @kidney_boy And the fact that baseline groups differed with respect to renal indices โ crt, UACR, even eGFR #NephJC |
| Roger Rodby @NephRodby Ali's @poyanmehr point is spot on #NephJC |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC ๐๐ผ https://t.co/ERXMI3qFB8 https://t.co/3kSVh4n1nT |
| Joel M. Topf, MD FACP @kidney_boy @NephJC @kidney_boy isn't that inevitable when you randomize 12 and 14 patients #nephjc |
| Nephrology Journal Club @NephJC @NephRodby You might need to wait for #statsmadness #nephjc |
 | Efraรญn J. Sรกnchez Angarita @efrasanchez RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC ๐๐ผ https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw |
| Nephrology Journal Club @NephJC RT @DoctorGates: @gratefull080504 It all depends on the eGFR where the patient stabilizes to stage the CKD. Unless you agree with the recent CJASN Aug issue #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Why were there no US investigators + sites for the Phase 2 trial? #nephJC |
| Joel M. Topf, MD FACP @kidney_boy @manirath thanks for coming #nephjc |
| Manish Rathi @manirath @NephJC Though not qualified Rheumat. Think it's a reasonable good marker for acute change #NephJC |
| Nephrology Journal Club @NephJC RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC ๐๐ผ https://t.co/ERXMI3qFB8 https://t.co/3kSVh4n1nT |
| Paul Sufka, MD @psufka @NephJC #nephJC BVAS is one of the most widely used measurement tools in research for systemic vasculitis. Well validated. |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Is #vasculitis considered a #raredisease ? #nephJC |
| Joel M. Topf, MD FACP @kidney_boy RT @JMGardnerMD: RT @BethBraunhut: RT @BethBraunhut: Gorgeous example of membranous nephropathy. Looks at those spikes! #pathology #pathArt #nephJC https://t.co/xAUlZfEUR4 |
| Manish Rathi @manirath RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC ๐๐ผ https://t.co/ERXMI3qFB8 https://t.co/3kSVh4n1nT |
| Nephrology Journal Club @NephJC @poyanmehr @kidney_boy But endpoints and discussion message not focussed on safety but efficacy #nephjc |
| Roger Rodby @NephRodby Form what I can tell, these are not the sick vasculitis patients I see with bad GN. not sure if results apply to my practice #NephJC |
| Poyan Mehr @poyanmehr @gratefull080504 @kidney_boy @poyanmehr @kidney_boy because FDA more a challenging barrier than european counter part - that simple #nephjc |
| Paul Sufka, MD @psufka @NephJC #NephJC but keep in mind that any tool that tries to convert how a pt is doing to a number will always be flawed. |
| Poyan Mehr @poyanmehr @gratefull080504 yes #nephjc |
| Manish Rathi @manirath Nice #NephJC https://t.co/YNNTxLmBN8 |
 | El. Miauricio Coronado. @MaudeNarvarte RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC ๐๐ผ https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw |
| Nephrology Journal Club @NephJC @psufka And comparable to other scores #NephJC https://t.co/a7h7pK29LW |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd @NephJC Birmingham Vasculitis Activity Score (BVAS) #Nephpearls #NephJC https://t.co/ynoptpT5AP |
| El. Miauricio Coronado. @MaudeNarvarte RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC ๐๐ผ https://t.co/ERXMI3qFB8 https://t.co/3kSVh4n1nT |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Is the UK patient organization more active than US counterpart in #patientadvocacy? Where is the #patientvoice in the US? #hcldr https://t.co/dBHZ6Karp0 |
 | Kartik Kalra MD,FNKF,FASN @kkalra_22 #nephjc |
| Arvind Canchi (Conjeevaram)๐ฎ๐ณ @arvindcanchi RT @edgarvlermamd: @NephJC Birmingham Vasculitis Activity Score (BVAS) #Nephpearls #NephJC https://t.co/ynoptpT5AP |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Never have heard of a Phase 2 study without one US trial site Never #nephjc https://t.co/dBHZ6Ks2NA |
| Poyan Mehr @poyanmehr @NephJC @kidney_boy that is where the confusion comes in. clearly not powered & designed for what we would like to see #nephjc |
| Manish Rathi @manirath Changes in BVAS is good in assessing change in ds activity #NephJC https://t.co/3oU3gr9VtC |
| Nephrology Journal Club @NephJC @NephRodby Sounds like they're more rheum than nephro #nephjc |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Where is the US #patientvoice? #nephJC https://t.co/dBHZ6Ks2NA |
| Poyan Mehr @poyanmehr @NephJC @kidney_boy but that is the very nature of early phase trial. to make sure no one dies, and that there is a signal to do ph3 #nephjc |
| Roger Rodby @NephRodby I wonder if the Europeans diagnose vasculitis sooner than in the states? Or selection bias as a nephrologist I see the sickest #NephJC |
| Kartik Kalra MD,FNKF,FASN @kkalra_22 #nephjc Hi Kartik Kalra Internal Medicine Resident. New Brunswick, NJ. No CoI. |
| Gates Colbert, MD @DoctorGates Do you need #Meningococcal vaccination prior to #Avacopan administration a la #Eculizumab ? Asking for a friend. #nephjc |
| Nephrology Journal Club @NephJC Excellent. Thanks @manirath https://t.co/9kKNGMoSFO |
| Pablo Garcia @PabloGarciaMD @kkalra_22 Welcome #nephjc |
| Joel M. Topf, MD FACP @kidney_boy But then published in JASN? RT @NephJC: @NephRodby Sounds like they're more rheum than nephro #nephjc |
| Joel M. Topf, MD FACP @kidney_boy RT @poyanmehr: @NephJC @kidney_boy but that is the very nature of early phase trial. to make sure no one dies, and that there is a signal to do ph3 #nephjc |
| Nephrology Journal Club @NephJC Methodology set up for one outcome - but results extrapolated to another. Thx @poyanmehr #nephjc https://t.co/oeSxkJWyJp |
 | goingtomedschool @going2medschool RT @JMGardnerMD: RT @BethBraunhut: RT @BethBraunhut: Gorgeous example of membranous nephropathy. Looks at those spikes! #pathology #pathArt #nephJC https://t.co/xAUlZfEUR4 |
| Roger Rodby @NephRodby @poyanmehr Yes not powered for that, but I would be reluctant to bail on steroids for RPGN #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @NephRodby : Why would that be? Please explain #nephJC https://t.co/g0r717E9Bn |
| Manish Rathi @manirath #NephJC https://t.co/M7B9OFwufT |
| Poyan Mehr @poyanmehr @NephRodby agree. average eGFR ~50, and borderline mostly microalbuminuria ?? #nephjc |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd @NephJC @NephRodby Not that there's anything wrong with that #NephJC https://t.co/6KcYw5w9zI |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Exactly @kidney_boy ! Why invest in this study + publish in JASN if not planned for #nephrology #nephJC https://t.co/UEPg5xdBNE |
| Nephrology Journal Club @NephJC @NephRodby Or referral bias? #nephjc |
| Poyan Mehr @poyanmehr @kidney_boy @NephJC @NephRodby and that is why i am excited about.. we are catching on w trials and exploring new opportunities #nephjc |
| Nephrology Journal Club @NephJC @gratefull080504 @NephRodby Someone with mild proteinuria might not be ref to nephro. Someone with AKI would be - so nephro see worse disease. #nephjc |
| Manish Rathi @manirath @NephJC @poyanmehr @kidney_boy Agree. They shud just have focused on safety for time being. Efficacy is added advantage to be explored in further studies #NephJC |
| Poyan Mehr @poyanmehr @NephRodby and if it is reproduced in a larger trial, powered for that endpoint? #nephjc |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Asking again: Is #vasculitis a #raredisease ? #nephJC |
| Joel M. Topf, MD FACP @kidney_boy This study is the tip of the spear. We are interested in it because it's a whole new promising drug. Very exciting. #nephjc |
| Nephrology Journal Club @NephJC This study ran over 5 years โ what else has changed in ANCA since then? Help a paed neph out - I don't see ANCA! #nephjc |
| Joel M. Topf, MD FACP @kidney_boy @gratefull080504 I believe so #nephjc |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @kidney_boy : Are their other potential other applications in #kidneydisease ? #nephJC https://t.co/rUYTZg00lG |
| Joel M. Topf, MD FACP @kidney_boy @NephJC between Steps 1 and 2 and Step 3 rituximab came on the scene and I think it has convinced just about everyone. #nephjc |
| Manish Rathi @manirath @NephJC Ritux has come in big way. Now the first line of tx #NephJC |
| Anitha Vijayan @VijayanMD @poyanmehr @NephRodby phase III trial has started. Rheum colleague at Wash U is involved in that one. #nephJC |
| Joel M. Topf, MD FACP @kidney_boy @gratefull080504 @kidney_boy Likely so, being a C5aR antagonist should make it useful in a number of compliments driven toxicities #nephjc |
| Roger Rodby @NephRodby I think I see them later in dz. sicker RT @gratefull080504 @NephRodby : Why would that be? Please explain #nephJC https://t.co/1ALj9i3cQj |
| Nephrology Journal Club @NephJC @gratefull080504 Yes overall but depends on the vasculitis. eg HSP not uncommon in childhood. #nephjc |
| Manish Rathi @manirath @NephJC The same group, EUVAS has published so much abt Ritux #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 The investigative compound did not lower proteinuria, correct? If correct,why ? #nephJC |
| Nephrology Journal Club @NephJC @gratefull080504 @kidney_boy There are always other potential applications! #nephjc |
| Nephrology Journal Club @NephJC RT @VijayanMD: @poyanmehr @NephRodby phase III trial has started. Rheum colleague at Wash U is involved in that one. #nephJC |
| Nephrology Journal Club @NephJC RT @manirath: @NephJC Ritux has come in big way. Now the first line of tx #NephJC |
 | Jeffrey Sparks MD MMSc @jeffsparks RT @NephJC: A huge shout out to our #rheumjc colleagues! Welcome to #nephjc |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @NephJC : such as ? #nephJC https://t.co/kK05h59XKG |
| Nephrology Journal Club @NephJC Yes, but we should've been more systematic as a community early on. Bliss trial was a major wake-up. #nephjc https://t.co/utFCmMaaYb |
| Poyan Mehr @poyanmehr @gratefull080504 I think advocacy groups are working to change that here.. not sure if for better or worse. 2 sided sword #nephjc |
| Paul Sufka, MD @psufka @NephJC #nephJC in the last 5 years, weโve shown RTX=CYC for induction, and RTX best for maint. Anything new has to=RTX, since so well tolerated. |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Is the @VasculitisFound on this chat? I hope so #nephJC |
| Jeffrey Sparks MD MMSc @jeffsparks @NephJC It is what is typically used #NephJC #RheumJC |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd @gratefull080504 ANCA Vasculitis #Rarediseases #NephJC ๐๐ผ https://t.co/3zm2rCzUlL https://t.co/vArXiaQYMc |
| Nephrology Journal Club @NephJC @gratefull080504 Every other vasculitis or complementopathy or nephrotic syndrome - we'll try anything there. #nephjc |
| Poyan Mehr @poyanmehr @gratefull080504 some of it, as usual, is $$ driven #NephJC |
| Jeffrey Sparks MD MMSc @jeffsparks RT @NephJC: Terrific summary (as always) from #nephpearls #nephjc https://t.co/FRGZuStKR5 |
| Cathy Quinlan @CathyQuinlan.bsky.social @KidneyCathy RT @psufka: @NephJC #nephJC in the last 5 years, weโve shown RTX=CYC for induction, and RTX best for maint. Anything new has to=RTX, since so well tolerated. |
| Roger Rodby @NephRodby Anything that spares or avoids steroids has Holy Grail potential #NephJC |
 | Liz McKinnon, MD @LilDocLiz1 RT @JMGardnerMD: RT @BethBraunhut: RT @BethBraunhut: Gorgeous example of membranous nephropathy. Looks at those spikes! #pathology #pathArt #nephJC https://t.co/xAUlZfEUR4 |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 The current standard of care for #vasculitis looks awful for quality of life + becoming a #kidneytransplant candidate, etc, #nephJC |
| Gates Colbert, MD @DoctorGates @NephJC @gratefull080504 Not uncommon, but still impressive. See Figure1 today in IG. https://t.co/vfwCusNhEv #NephJC |
| Cathy Quinlan @CathyQuinlan.bsky.social @KidneyCathy REduced UACR according to table 2 #nephjc https://t.co/Cc2UKgb03B |
| Poyan Mehr @poyanmehr RT @NephRodby: Anything that spares or avoids steroids has Holy Grail potential #NephJC |
| Joel M. Topf, MD FACP @kidney_boy RT @NephRodby: Anything that spares or avoids steroids has Holy Grail potential #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 This is partially explains #pharma interest in #vasculitis #raredisease #nephJC https://t.co/C9S7ubb6de |
| Nephrology Journal Club @NephJC @gratefull080504 Patient perspective - generally positive towards GCs #nephJC Need more patient involvement in setting study outcomes @song_initiative |
| Roger Rodby @NephRodby I could not find: All pts got CTX or RTX first, was pulse steroids given too? #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @KidneyCathy : I saw that but does it take a longer time to reduce proteinuria ? #nephJC https://t.co/rWzaBz4f1w |
| Nephrology Journal Club @NephJC Does anyone know what Ava will cost? #NephJC |
| Poyan Mehr @poyanmehr @gratefull080504 yes, but just that these little kids have nothing to do with ANCA.. but who cares when we are in selling business #nephjc |
| Joel M. Topf, MD FACP @kidney_boy @NephJC how thick is your wallet? #nephjc |
| Anitha Vijayan @VijayanMD @gratefull080504 @NephJC atypical HUS, C3 glomerulopathy #nephJC |
| Roger Rodby @NephRodby @KidneyCathy reduced AER, but was low to start with, doesn't mean that much #NephJC |
| Poyan Mehr @poyanmehr @NephJC depend on the phaseIII. sky is the limit... #nephjc |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @NephJC : I saw Celeste suffer from long-term use of GC cumulative toxicity Where are the patients tonight? #nephJC https://t.co/8oWuQE3W1K |
| Nephrology Journal Club @NephJC @NephRodby I couldn't find that either - surprised if they didn't but not mentioned. #nephjc |
| Roger Rodby @NephRodby $ > rituxan < Acthar ? #NephJC |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd Monitoring of ANCA Vasculitis #Nephpearls #NephJC ๐๐ผ https://t.co/rgHGtKPM6M https://t.co/GlfK1OTdaA |
 | V. Ocampo D @vod_md RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo |
 | Nalin Yadav @DrNalinYadav RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC ๐๐ผ https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw |
| Roger Rodby @NephRodby Pulse steroids is important, we have no idea just how long that lasts, my gut is that pulsing is like weeks of po steroids #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 What is the primary endpoint for Phase III trial? #nephJC |
| Michelle Rheault @rheault_m @gratefull080504 GPA incidence 0.5-10/million depending on diagnostic criteria and population #NephJC https://t.co/OFUS0JM1Y7 https://t.co/lA4rACw67R |
| Nalin Yadav @DrNalinYadav RT @edgarvlermamd: Monitoring of ANCA Vasculitis #Nephpearls #NephJC ๐๐ผ https://t.co/rgHGtKPM6M https://t.co/GlfK1OTdaA |
| Poyan Mehr @poyanmehr @NephJC @NephRodby and i could not see the proportions of type of induction. did i miss?. #nephjc |
| Roger Rodby @NephRodby No difference in adverse event % bit nature of adverse events very different #NephJC |
| Roger Rodby @NephRodby @poyanmehr The devil is, always, in the details #NephJC |
 | Kalyani Bambal @kriyer68 RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo |
| Poyan Mehr @poyanmehr RT @NephRodby: @poyanmehr The devil is, always, in the details #NephJC |
| Nephrology Journal Club @NephJC @poyanmehr @NephRodby No - I can't find it either #nephjc |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd ANCA Vasculitis: Predictors of treatment relapse/ resistance #Nephpearls #NephJC https://t.co/sBKk4ek8uS |
| Roger Rodby @NephRodby regardless, targeted therapies are the future #NephJC |
| Anitha Vijayan @VijayanMD @gratefull080504 Induction of remission https://t.co/Kk28sxaQeK #nephJC |
| Poyan Mehr @poyanmehr @gratefull080504 this is the link to trials registration site.. remission is the prim. outcome https://t.co/IVU1yEz4Xo #nephjc |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 ๐ฒ๐ฝ https://t.co/xOF06Lcmdu |
| Roger Rodby @NephRodby Even though we save a life every time we dialyze, nothing is like bringing someone back from the dead from vasculitis #NephJC |
| Nephrology Journal Club @NephJC RT @rheault_m: @gratefull080504 GPA incidence 0.5-10/million depending on diagnostic criteria and population #NephJC https://t.co/OFUS0JM1Y7 https://t.co/lA4rACw67R |
| Arvind Canchi (Conjeevaram)๐ฎ๐ณ @arvindcanchi RT @edgarvlermamd: MT @arvindcanchi @ISNeducation ANCA Vasculitis: MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 ๐ฒ๐ฝ https://t.co/xOF06Lcmdu |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd @NephRodby Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC ๐๐ผ https://t.co/CCru5MyqE4 https://t.co/mPOpKDaM2y |
| Nephrology Journal Club @NephJC @poyanmehr @gratefull080504 How is remission defined by BVS - 50% reduction or more? #nephjc |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Amen #nephJC https://t.co/NtkTGaZCLt |
| Roger Rodby @NephRodby Jayne, lead author, also lead of https://t.co/im2ajiRPqP, no stranger to vasculitis #NephJC |
| Nephrology Journal Club @NephJC @NephRodby And both therapies have side effects and long term concerns. #nephjc |
| Nephrology Journal Club @NephJC Love this diagram - it's going on my wall! #nephpearls #nephjc https://t.co/ZAEQreok23 |
 | george miguelito @georgemiguelito RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo |
| Roger Rodby @NephRodby @NephJC I could draw that diagram in my sleep. #NephJC |
| Nephrology Journal Club @NephJC At the risk of repetition - one of the core goals of #nephJC is to build a personal learning network so make sure to hit the follow button |
| Wings Implied @Wingsimplied RT @NephRodby: Anything that spares or avoids steroids has Holy Grail potential #NephJC |
| Nephrology Journal Club @NephJC So in summary, flawed methodology - interesting drug - potential to reduce GC use in early disease. Would you use it? #NephJC #nephjc |
| Poyan Mehr @poyanmehr @NephJC why flawed methodology ? what did i miss? #nephjc |
| Poyan Mehr @poyanmehr @NephJC no way i would use it. we don't know yet if it is effective.. i would wait for larger trial #nephjc |
| Cathy Quinlan @CathyQuinlan.bsky.social @KidneyCathy @NephJC Would need to see some paeds data first and something beyond ANCA #nephjc |
| Nephrology Journal Club @NephJC @poyanmehr methodology set up for safety but conclusions drawn re efficacy. Am I overcalling? #nephjc |
 | Nathaniel Reisinger @nephrothaniel I definitely have been lurking #nephJC the whole time instead of participating in the #NBLUniv happy hour!! |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd C-ANCA Chocolate chip cookie ๐ช P-ANCA Popcorn ๐ฟ Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs |
| Roger Rodby @NephRodby @NephJC "not ready for prime time" at least for me right now #NephJC |
| Manish Rathi @manirath RT @edgarvlermamd: MT @arvindcanchi @ISNeducation ANCA Vasculitis: MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 ๐ฒ๐ฝ https://t.co/xOF06Lcmdu |
| Nephrology Journal Club @NephJC @poyanmehr Feels like Ritux hit the wards with similarly limited data... #nephjc |
| Nephrology Journal Club @NephJC Thanks you to everyone who took part and to all the lurkers, itโs been fun! #NephJC https://t.co/ya2bDr7kyf |
 | Adriana Bello @adrianabello RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC ๐๐ผ https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw |
| Manish Rathi @manirath @NephJC Too early to say. Let it prove it's worth first ๐#NephJC |
| Poyan Mehr @poyanmehr @NephJC well they need to show that it is safe, but they also need to show rationale for doing a larger study. i think they did. #nephjc |
| Joel M. Topf, MD FACP @kidney_boy Great chat guys! #nephjc |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @NephJC : Please explain why methodology is flawed? How can you make a prescribing decision of Phase 2 results? #nephJC https://t.co/aUle62xCiY |
| Gates Colbert, MD @DoctorGates #Avacopan - exciting drug, interesting article previewing its potential to the #Vasculitis world with this publication. Will see! #nephjc |
 | Mayuri Trivedi @MayuriTrivedi80 RT @edgarvlermamd: MT @arvindcanchi @ISNeducation ANCA Vasculitis: MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 ๐ฒ๐ฝ https://t.co/xOF06Lcmdu |
| Joel M. Topf, MD FACP @kidney_boy But ready for a phase 3 for sure! RT @NephRodby: @NephJC "not ready for prime time" at least for me right now #NephJC |
| Nephrology Journal Club @NephJC RT @poyanmehr: @NephJC well they need to show that it is safe, but they also need to show rationale for doing a larger study. i think they did. #nephjc |
| Mayuri Trivedi @MayuriTrivedi80 RT @NephJC: Love this diagram - it's going on my wall! #nephpearls #nephjc https://t.co/ZAEQreok23 |
| Mayuri Trivedi @MayuriTrivedi80 RT @edgarvlermamd: ANCA Vasculitis: ANCA Vasculitis: Predictors of treatment relapse/ resistance #Nephpearls #NephJC https://t.co/sBKk4ek8uS |
| Poyan Mehr @poyanmehr @NephJC but i agree, that the manuscript could have been more clear on the nature and purpose of trial #nephjc |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Key question: How can this potential treatment improve the #vasculitis patient journey? What is the potential value prop? #nephJC https://t.co/aUle62xCiY |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @poyanmehr : I have the same question #nephJC https://t.co/sfMWvIUlil |
| Joel M. Topf, MD FACP @kidney_boy Thanks Cathy, great job hosting from down under! I liked how your tweets went counter-clockwise #nephjc |
| Edgar V. Lerma ๐ต๐ญ @edgarvlermamd @NephJC Agree with @NephRodby Not ready for prime time #NephJC https://t.co/Qm3vy0cHSu |
| Roger Rodby @NephRodby @kidney_boy For sure needs phase 3, wish patients were sicker, but they probably won't be, not a neph trial #NephJC |
 | ุฃุญุจู ุฑุจู . @UAEforEver1 RT @edgarvlermamd: C-ANCA Chocolate chip cookie ๐ช P-ANCA Popcorn ๐ฟ Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs |
| Nephrology Journal Club @NephJC @gratefull080504 MAybe I'm overstating but I don't think you can draw conclusions about efficacy from a trial set up to assess safety. #nephjc |
| Mayuri Trivedi @MayuriTrivedi80 RT @NephRodby: Even though we save a life every time we dialyze, nothing is like bringing someone back from the dead from vasculitis #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Is a medication ever ready for primetime after only Phase 2? #nephJC https://t.co/6r26ErXIPR |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @NephJC: Agreed but efficacy was not the primary endpoint, correct? #nephJC https://t.co/iKdeZbvwrh |
| Manish Rathi @manirath @edgarvlermamd @MayuriTrivedi80 I think renal involvement & it's severity is also one of the strong predictor of outcome #NephJC @NephJC |
| Nephrology Journal Club @NephJC Another potential therapy in the future armory. More data needed. Good to see targeted therapies. #nephjc https://t.co/w9ItQEgZyz |
| Nephrology Journal Club @NephJC RT @NephRodby: @kidney_boy For sure needs phase 3, wish patients were sicker, but they probably won't be, not a neph trial #NephJC |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @NephJC : Without a doubt! #nephJC https://t.co/R9WPhsXCBi |
| Manish Rathi @manirath Nice interaction. Learnt a lot. Thanks #NephJC https://t.co/frVSW0xfYZ |
| Manish Rathi @manirath RT @NephJC: Another potential therapy in the future armory. More data needed. Good to see targeted therapies. #nephjc https://t.co/w9ItQEgZyz |
| Roger Rodby @NephRodby No wuckers , Hoo roo/Oooroo , Cheers mates, https://t.co/aiQ03VXnec #NephJC |
| Nephrology Journal Club @NephJC Yes. We'll have to wait for phase 3. However abstract conc (all that will b read by most) states effective in replacing GCs. #nephjc https://t.co/FJ7CmSvxkZ |
| Gerardo Alfaro @gerardoalfaromd RT @edgarvlermamd: C-ANCA Chocolate chip cookie ๐ช P-ANCA Popcorn ๐ฟ Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @NephJC : Based upon potential improvement in quality of life safety #nephJC https://t.co/yYdZTLEmeR |
 | ISN Education @ISNeducation @edgarvlermamd @arvindcanchi This might be of interest from @macotav https://t.co/cv6m1TCwmg #nephJC #Nephpearls |
| Joel M. Topf, MD FACP @kidney_boy The numbers: 307 Tweets. 61 Participants. August 7th 2017. More #NephJC ๐ here https://t.co/T5dkn5tEE6 via @symplur |
| Cathy Quinlan @CathyQuinlan.bsky.social @KidneyCathy Thx to #nephjc for showing me what parenting octuplets would be like! Now Grand Rounds with the amazing Laila! @RCHMelbourne @MCRI_for_kids |
| Roger Rodby @NephRodby RT @poyanmehr: @gratefull080504 this is the link to trials registration site.. remission is the prim. outcome https://t.co/IVU1yEz4Xo #nephjc |
 | Didem Saygin, MD @DidemSayginMD RT @edgarvlermamd: C-ANCA Chocolate chip cookie ๐ช P-ANCA Popcorn ๐ฟ Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs |
 | Dr. Divya Bajpai ๐ฎ๐ณ @divyaa24 RT @edgarvlermamd: C-ANCA Chocolate chip cookie ๐ช P-ANCA Popcorn ๐ฟ Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs |
#NephJC content from Twitter.